fulvestrant has been researched along with raloxifene in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Birzin, ET; Blizzard, TA; Chan, W; Chen, HY; DaSilva, CA; DiNinno, F; Hammond, ML; Hayes, EC; Kim, S; Pai, LY; Rohrer, SP; Schaeffer, JM; Wu, JY; Yang, YT | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Chen, T; Forman, BM; Lin, W; Yu, DD | 1 |
| Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hashimoto, Y; Makishima, M; Nanjyo, S; Noguchi-Yachide, T; Ohgane, K; Yoshioka, H | 1 |
| Chinnaswamy, K; Delproposto, J; Hayes, DF; Hu, B; Hu, J; Liu, Z; Miao, B; Stuckey, J; Wang, M; Wang, S; Xu, F; Yang, CY | 1 |
| Chen, H; Dubrovyskyii, O; Dye, K; Gordon-Blake, J; Gutgesell, LM; He, D; Hollas, M; Huang, F; Lasek, AW; Lee, S; Li, Y; Lu, Y; Rosales, CI; Shen, Z; Thatcher, GRJ; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Bai, C; Luo, G; Ren, S; Wu, S; Xiang, H; Zhu, M | 1 |
1 review(s) available for fulvestrant and raloxifene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for fulvestrant and raloxifene
| Article | Year |
|---|---|
Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Humans; Oxathiins; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Uterus | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
Topics: Biological Assay; Drug Discovery; Fluoresceins; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Gene Expression Regulation; Isoxazoles; Molecular Structure; Protein Binding; Receptors, Cytoplasmic and Nuclear | 2013 |
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship | 2016 |
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
Topics: Benzhydryl Compounds; Binding Sites; Cyclofenil; Down-Regulation; Estrogen Antagonists; Estrogen Receptor alpha; HEK293 Cells; Humans; Molecular Docking Simulation; Phenols; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship | 2019 |
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dipeptides; Drug Design; Drug Screening Assays, Antitumor; Humans; Ligands; Molecular Structure; Proteolysis; Pyrrolidines; Receptors, Estrogen; Structure-Activity Relationship; Thiophenes; Ubiquitin-Protein Ligases | 2019 |
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Proteolysis; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Thiophenes; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Estrogen Receptor Antagonists; Female; Humans; MCF-7 Cells; Molecular Structure; Receptors, Estrogen; Structure-Activity Relationship; Thiophenes; Tumor Cells, Cultured | 2021 |